Drug intelligence / Profile preview

XSTEM

Development stage: Preclinical
Lead developer: Xintela
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular

Overview

XSTEM is a stem cell therapy product developed by Xintela. It utilizes Xintela's proprietary marker technology platform (XINMARK), which is based on specific cell surface proteins (integrins), to select and quality assure stem cells for therapeutic use. The primary indication under development is osteoarthritis, particularly knee osteoarthritis, where current treatment options are limited. XSTEM is being prepared for First in Human clinical studies targeting patients with knee osteoarthritis[8].

Brand names: xstem
Other names: xstem

Targets

α10β1 (Integrin alpha 10 beta 1)

Beyond the preview

Go deeper on XSTEM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XSTEM.

Explore the full profile